Literature DB >> 9702971

Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia.

J G Vieira1, T T Tachibana, L H Obara, R M Maciel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9702971

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  15 in total

1.  Editorial: is macroprolactinemia just a diagnostic pitfall?

Authors:  Marcello D Bronstein
Journal:  Endocrine       Date:  2012-04       Impact factor: 3.633

2.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

3.  Clinical and radiological findings in macroprolactinemia.

Authors:  Serhat Isik; Dilek Berker; Yasemin Ates Tutuncu; Ufuk Ozuguz; Ferhat Gokay; Gonul Erden; Hatice Nursun Ozcan; Ferit Kerim Kucukler; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2011-12-21       Impact factor: 3.633

4.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

5.  New splicing mutation of MEN1 gene affecting the translocation of menin to the nucleus.

Authors:  H P Tala; C A Carvajal; A A González; J L Garrido; J Tobar; A Solar; C Campino; E Arteaga; C E Fardella
Journal:  J Endocrinol Invest       Date:  2006-11       Impact factor: 4.256

6.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

7.  Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; F Dal Bosco
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

8.  Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.

Authors:  L Vilar; M C Freitas; L A Naves; L A Casulari; M Azevedo; R Montenegro; A I Barros; M Faria; G C Nascimento; J G Lima; L H Nóbrega; T P Cruz; A Mota; A Ramos; A Violante; A Lamounier Filho; M R Gadelha; M A Czepielewski; A Glezer; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2008-05       Impact factor: 4.256

9.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

10.  Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin.

Authors:  Christopher R McCudden; Julie L Sharpless; David G Grenache
Journal:  Clin Chim Acta       Date:  2009-11-04       Impact factor: 3.786
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.